Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001065701 | SCV001230673 | likely pathogenic | Bifunctional peroxisomal enzyme deficiency; Perrault syndrome | 2019-02-13 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly16 amino acid residue in HSD17B4. Other variant(s) that disrupt this residue have been observed in individuals with HSD17B4-related conditions (PMID: 9482850, 25967389, 27290639, 26970254, 16385454, 9915948), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. This variant has not been reported in the literature in individuals with HSD17B4-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change affects the initiator methionine of the HSD17B4 mRNA. The next in-frame methionine is located at codon p.148. |